DE-INCYTE
14.5.2020 18:20:09 CEST | Business Wire | Press release
Incyte (Nasdaq: INCY) today announced that multiple abstracts highlighting data from clinical trials of medicines that are being developed in-house and through partnerships with Novartis, MorphoSys and Takeda will be presented at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31); and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14).
“We are pleased to have virtual platforms such as ASCO20 and EHA25 to continue sharing important data with the scientific community in a timely manner,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “These data demonstrate the strength of our broad oncology portfolio and our partnerships; and reinforce our commitment to finding solutions that can help meet patients’ needs.”
Key abstracts accepted by ASCO and EHA include:
ASCO Abstracts
Oral, poster discussion and poster sessions, as well as track-based clinical science symposia, accepted for presentation at ASCO will be available on demand beginning Friday, May 29, 2020, 8:00 AM ET.
Oral Presentations
Capmatinib in Patients with High-Level MET -Amplified Advanced Non-Small Cell Lung Cancer (NSCLC): Results from the Phase 2 GEOMETRY mono-1 Study (Abstract #9509, Session: MET Mutations: The Meat of the Matter)1
Interim Analysis (IA) of OPTIC: A Dose-Ranging Study of Three Ponatinib (PON) Starting Doses (Abstract #7502, Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant)2
E-Poster Presentations
An Independent Review of Arterial Occlusive Events (AOEs) in the Ponatinib (PON) Phase 2 PACE Trial (NCT01207440) in Patients (pts) with Ph+ Leukemia (Abstract #7550, Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant)2
Re-MIND Study: A Propensity Score-Based 1:1 Matched Comparison of Tafasitamab + Lenalidomide (L-MIND) Versus Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) (Abstract #8020, Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia)3
Safety and Efficacy of Pemigatinib Plus Pembrolizumab Combination Therapy in Patients (pts) with Advanced Malignancies: Results from FIGHT-101, an Open-Label Phase 1/2 study (Abstract #3606, Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology)
Capmatinib in Patients with METex14 -Mutated or High-Level MET -Amplified Advanced Non-Small-Cell Lung Cancer (NSCLC): Results from Cohort 6 of the Phase 2 GEOMETRY mono-1 study (Abstract #9520, Session: Lung Cancer—Non-Small Cell Metastatic)1
Pan-Cancer Analysis of FGFR1-3 Genomic Alterations to Reveal a Complex Molecular Landscape (Abstract #3620, Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology)
EHA Abstracts
Oral abstract presentations and e-posters accepted for presentation at EHA will be available on the on-demand Virtual Congress platform beginning Friday, June 12, 2020, at 8:30 AM CEST.
Oral Presentations
Addition of Parsaclisib, a PI3Kδ inhibitor, in Patients with Suboptimal Response to Ruxolitinib (Rux): A Phase 2 Study in Patients (Pts) with Myelofibrosis (MF) (Abstract #S216, Session: Novel Therapies and Pitfalls in MPN)
Ruxolitinib Versus Best Available Therapy in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease: Overall Response Rate by Baseline Characteristics in the Randomized Phase 3 REACH2 Trial (Abstract #S255, Session: Stem Cell Transplantation – Clinical: Graft-Versus-Host Disease)1
GRAVITAS-301: A Randomized, Double-Blind Phase 3 Study of Itacitinib or Placebo in Combination with Corticosteroids for Initial Treatment of Patients with Acute Graft-Versus-Host Disease (Abstract #S256, Session: Stem Cell Transplantation – Clinical: Graft-Versus-Host Disease)
Interim Analysis from the OPTIC Trial, a Dose-Ranging Study of 3 Starting Doses of Ponatinib (Abstract #S172, Session: Chronic Myeloid Leukemia (CML) Clinical)2
Re-MIND Study: Comparison of Tafasitamab + Lenalidomide (L-Mind) vs Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Abstract #S238, Aggressive Lymphomas: Observational Studies)3
E-Poster Presentations
Real-World Survival in Elderly Patients with Myelofibrosis in the United States: Ruxolitinib Exposed vs Unexposed (Abstract #EP1124, Session: Myeloproliferative Neoplasms – Clinical)
Real-World Survival in Elderly Patients with Myelofibrosis in the United States: Pre- vs Post-Ruxolitinib Approval (Abstract # EP1120, Session: Myeloproliferative Neoplasms – Clinical)
Machine-Learning to Predict Hydroxyurea (HU) Failure and Incidence of Thromboembolic Events (TEs) with HU vs Ruxolitinib Switch Therapy in Polycythemia Vera Patients (Abstract #EP1117, Session: Myeloproliferative Neoplasms – Clinical)1
Patient-Reported Physical, Emotional and Economic Impact of Myeloproliferative Neoplasms in an Expansion of the MPN Landmark Survey (Abstract #EP1112, Session: Myeloproliferative Neoplasms – Clinical)1
Ruxolitinib in PV Patients Resistant and/or Intolerant to Hydroxyurea: Interim Analysis of a European Multi-Centric Observational Study (Abstract #EP1115, Session: Myeloproliferative Neoplasms – Clinical)1
Treatment and Disease Management Practices in Patients with MPNs in 6 Countries: An Expansion of the MPN Landmark Survey (Abstract #EP1123, Session: Myeloproliferative Neoplasms – Clinical)1
Retrospective Independent Review of Arterial Occlusive Events (AOEs) in the Phase 2 PACE Trial of Ponatinib in Philadelphia Chromosome Positive (Ph+) Leukemia (Abstract #EP759, Session: Chronic Myeloid Leukemia (CML) Clinical)2
The Real–Life Study Evaluating the Efficacy and Safety of Ponatinib “Topase” Reveals Induction of Deep Molecular Responses in a Cohort of 75 TKI-Resistant or Intolerant patients with CML (Abstract #EP765, Session: Chronic Myeloid Leukemia (CML) Clinical)
Combination of Tafasitamab (MOR208) and Lenalidomide Enhances Tumor Cell Death of B-cell Lymphoma in Vitro (Abstract #EP1343, Session: Lymphoma Biology & Translational Research)3
Long-Term Outcomes from the Phase II L-MIND Study of Tafasitamab (Mor208) Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Abstract #EP1201, Session: Aggressive Non-Hodgkin Lymphoma - Clinical)3
Expression of CD19 Antigen on Chronic Lymphocytic Leukemia Cells After Tafasitamab (Anti-CD19) Treatment: Phase I Trial Data (Abstract #EP671, Chronic Lymphocytic Leukemia and Related Disorders - Biology & Translational Research)3
For full session details and data presentation listings, please see the ASCO20 (https://meetinglibrary.asco.org ) and EHA25 (https://learningcenter.ehaweb.org/eha ) online programs.
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com
and follow @Incyte
.
Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from the Company’s or partner company’s ongoing clinical development pipeline, and whether or when any development compounds will be approved or commercially available for use in humans anywhere in the world outside of the already approved indications in specific regions, its presentation plans for the upcoming ASCO and EHA meetings and its goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA; the Company’s dependence on its relationships with its collaboration partners; the efficacy or safety of the Company’s products and the products of the Company’s collaboration partners; the acceptance of the Company’s products and the products of the Company’s collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its Form 10-K for the year ended March 31, 2020. The Company disclaims any intent or obligation to update these forward-looking statements.
1 Novartis-sponsored; 2 Takeda-sponsored; 3 MorphoSys-sponsored
View source version on businesswire.com: https://www.businesswire.com/news/home/20200514005695/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom